• Asian Pacific Journal of Cancer Prevention
• /
• 제14권11호
• /
• pp.6721-6726
• /
• 2013

Background: Changes in DNA methylation patterns are believed to be early events in hepatocarcinogenesis. A better understanding of methylation states and how they correlate with disease progression will aid in finding potential strategies for early detection of HCC. The aim of our study was to analyze the methylation frequency of tumor suppressor genes, P14, P15, and P73, and a mismatch repair gene (O6MGMT) in HCV related chronic liver disease and HCC to identify candidate epigenetic biomarkers for HCC prediction. Materials and Methods: 516 Egyptian patients with HCV-related liver disease were recruited from Kasr Alaini multidisciplinary HCC clinic from April 2010 to January 2012. Subjects were divided into 4 different clinically defined groups - HCC group (n=208), liver cirrhosis group (n=108), chronic hepatitis C group (n=100), and control group (n=100) - to analyze the methylation status of the target genes in patient plasma using EpiTect Methyl qPCR Array technology. Methylation was considered to be hypermethylated if >10% and/or intermediately methylated if >60%. Results: In our series, a significant difference in the hypermethylation status of all studied genes was noted within the different stages of chronic liver disease and ultimately HCC. Hypermethylation of the P14 gene was detected in 100/208 (48.1%), 52/108 (48.1%), 16/100 (16%) and 8/100 (8%) among HCC, liver cirrhosis, chronic hepatitis and control groups, respectively, with a statistically significant difference between the studied groups (p-value 0.008). We also detected P15 hypermethylation in 92/208 (44.2%), 36/108 (33.3%), 20/100 (20%) and 4/100 (4%), respectively (p-value 0.006). In addition, hypermethylation of P73 was detected in 136/208 (65.4%), 72/108 (66.7%), 32/100 (32%) and 4/100 (4%) (p-value <0.001). Also, we detected O6MGMT hypermethylation in 84/208 (40.4%), 60/108 (55.3%), 20/100 (20%) and 4/100 (4%), respectively (p value <0.001. Conclusions: The epigenetic changes observed in this study indicate that HCC tumors exhibit specific DNA methylation signatures with potential clinical applications in diagnosis and prognosis. In addition, methylation frequency could be used to monitor whether a patient with chronic hepatitis C is likely to progress to liver cirrhosis or even HCC. We can conclude that methylation processes are not just early events in hepatocarcinogenesis but accumulate with progression to cancer.

• 생명과학회지
• /
• 제27권10호
• /
• pp.1207-1214
• /
• 2017

노화에 따른 퇴행성관절염은 삶의 질을 저하시키는 가장 큰 병리학적 현상 중의 하나이다. 오미자 열매(Schisandrae Fructus)는 오랫동안 전통의학에서 여러 가지 만성질환 치료를 위해 널리 사용되어 왔다. 오미자 추출물이 SW1353 인간 연골세포에서 $IL-1{\beta}$에 의해 유발된 염증 반응을 감소시키는 것으로 최근 보고된 바 있으나, primary culture된 연골세포 및 동물 모델에서의 퇴행성관절염에 대한 보호 및 치료 잠재력은 여전히 명확하지 않다. 따라서 본 연구에서는 $IL-1{\beta}$에 의해 유도된 primary culture된 쥐의 연골세포와 MIA에 의해 유도된 골관절염에 대한 matrix metalloproteinases (MMPs)의 활성에 미치는 오미자 에탄올 추출물의 영향을 조사하였다. 오미자 추출물 처리는 $IL-1{\beta}$로 유도된 연골세포에서 MMP-1, -3 및 -13의 mRNA 발현 및 효소 활성을 유의하게 감소시켰다. 또한 오미자 추출물은 MIA에 의해 증가된 MMP-1 및 -3의 발현을 유의적으로 억제시켰다. 따라서 오미자 추출물은 퇴행성관절염 예방과 치료를 위한 기능성 소재로서의 잠재적 가능성이 있음을 알 수 있었다.